HAMNO (NSC111847)
(Synonyms: NSC111847) 目录号 : GC34146
A small molecule inhibitor of replication protein A
Cas No.:138736-73-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | Cell cycle assessment and γ-H2AX staining are monitored in UMSCC38 and OKF4 cells after 2 h incubation with HAMNO (2, 20, 50 μM) and fixed in 70% ethanol overnight. Cells are washed with PBS and incubated overnight in PBS containing 1% BSA, 10% goat serum and PS139-H2AX antibodies, washed and incubated in goat anti-mouse Alexa Fluor 647 antibody for 30 min at room temperature. Cells are incubated in 50 μg/mL propidium iodide and 100 μg/mL RNase A for 30 min, and 10,000 cells per sample are analyzed[1]. |
Animal experiment: | Athymic nude mice are used in this study. UMSCC38 and UMSCC11B cells are implanted into 6-week-old female mice by a single subcutaneous injection of tumor cells (2 to 6×105 cells in 100 mL of sterile PBS). The growth rates of tumors are determined by daily monitoring of tumor volume with vernier calipers [tumor volume=1/2(length×width2)]. Once the tumor size reaches 50 mm3, etoposide (10 mg/kg mouse) and HAMNO (2 mg/kg) are administered intraperitoneally every day for 3 days. Tumor size is monitored daily and the volume of the tumor is compared among all experimental groups. At least three mice are used per group[1]. |
References: [1]. Glanzer JG, et al. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72. | |
HAMNO is a small molecule inhibitor of replication protein A (RPA).1 It selectively binds to and inhibits DNA binding domain F (DBD-F) on RPA70 when used at concentrations up to 100 ?M. HAMNO inhibits etoposide-induced autophosphorylation of ATR kinase and subsequent phosphorylation of RPA32 in UMSCC38 cells when used at concentrations of 10 and 20 ?M. HAMNO (1 mg/kg), in combination with etoposide , reduces tumor growth in UMSCC11B and UMSCC38 mouse xenograft models.
1.Glanzer, J.G., Liu, S., Wang, L., et al.RPA inhibition increases replication stress and suppresses tumor growthCancer Res.74(18)5165-5172(2014)
| Cas No. | 138736-73-9 | SDF | |
| 别名 | NSC111847 | ||
| Canonical SMILES | O=C(C=CC1=C/2C=CC=C1)C2=C/NC3=CC=CC=C3O | ||
| 分子式 | C17H13NO2 | 分子量 | 263.29 |
| 溶解度 | DMSO : 155 mg/mL (588.70 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7981 mL | 18.9905 mL | 37.9809 mL |
| 5 mM | 0.7596 mL | 3.7981 mL | 7.5962 mL |
| 10 mM | 0.3798 mL | 1.899 mL | 3.7981 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Xiphodynia
Editorial Comment
Reply to letter from T. Shigemura and H. Hamano
The authors reply
Pleomorphic Pulmonary Manifestations of IgG4-Related Disease
Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory disorder which has been first reported in 2001 by Hamano and colleagues in a patient with autoimmune sclerosing pancreatitis. Almost every organ in the human body can be affected by IgG4-RD from infiltration with IgG4-positive plasma cells. Involvement of lungs with IgG4 is reported previously, but still, there is no clear picture of the pathophysiology behind lung involvement. Here, we are presenting a patient who has IgG4-RD presenting as pseudotumor of the lungs.